Patents by Inventor Robert R. Whittle

Robert R. Whittle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Estrogenic compounds, pharmaceutical compositions and formulations comprising the same
    Patent number: 8227454
    Abstract: Novel estrogenic compounds of Formula I are provided. wherein the bond represented by the wavy line may be a single or double bond such that when the wavy line is a single bond, R1 is selected from the group consisting of hydrogen, sulfate and glucoronate or other esters, and when the wavy line is a double bond, R1 does not exist; R2 is lower alkyl; R3 may be selected from the group consisting of hydrogen, sulfate, or glucuronide or other esters; and R4 through R13 may independently be selected from the group consisting of hydrogen, hydroxy, ketone, lower alkyl, lower alkoxy, halogen, and carbonyl groups and R14 is selected from the group consisting of hydrogen, sulfate and glucoronide and other esters. When R1 is hydroxy, the hydroxy or ester substituent may have either an ? or a ? orientation. Compositions of matter including compounds of the present invention are also provided as are methods of treating mammals in need of treatment using compounds of the present invention.
    Type: Grant
    Filed: June 23, 2011
    Date of Patent: July 24, 2012
    Assignee: Duramed Pharmaceuticals, Inc.
    Inventors: Edward N. Hill, Frederick D. Sancilio, Robert R. Whittle
  • NOVEL ESTROGENIC COMPOUNDS
    Publication number: 20110269725
    Abstract: Novel estrogenic compounds of Formula I are provided. wherein the bond represented by the wavy line may be a single or double bond such that when the wavy line is a single bond, R1 is selected from the group consisting of hydrogen, sulfate and glucoronate or other esters, and when the wavy line is a double bond, R1 does not exist; R2 is lower alkyl; R3 may be selected from the group consisting of hydrogen, sulfate, or glucuronide or other esters; and R4 through R13 may independently be selected from the group consisting of hydrogen, hydroxy, ketone, lower alkyl, lower alkoxy, halogen, and carbonyl groups and R14 is selected from the group consisting of hydrogen, sulfate and glucoronide and other esters. When R1 is hydroxy, the hydroxy or ester substituent may have either an ? or a ? orientation. Compositions of matter including compounds of the present invention are also provided as are methods of treating mammals in need of treatment using compounds of the present invention.
    Type: Application
    Filed: June 23, 2011
    Publication date: November 3, 2011
    Inventors: Edward N. Hill, Frederick D. Sancilio, Robert R. Whittle
  • Estrogenic compounds and pharmaceutical formulations comprising the same
    Patent number: 7989436
    Abstract: Novel estrogenic compounds of Formula I are provided. wherein the bond represented by the wavy line may be a single or double bond such that when the wavy line is a single bond, R1 is selected from the group consisting of hydrogen, sulfate and glucoronate or other esters, and when the wavy line is a double bond, R1 does not exist; R2 is lower alkyl; R3 may be selected from the group consisting of hydrogen, sulfate, or glucuronide or other esters; and R4 through R13 may independently be selected from the group consisting of hydrogen, hydroxy, ketone, lower alkyl, lower alkoxy, halogen, and carbonyl groups and R14 is selected from the group consisting of hydrogen, sulfate and glucoronide and other esters. When R1 is hydroxy, the hydroxy or ester substituent may have either an ? or a ? orientation. Compositions of matter including compounds of the present invention are also provided as are methods of treating mammals in need of treatment using compounds of the present invention.
    Type: Grant
    Filed: May 27, 2010
    Date of Patent: August 2, 2011
    Assignee: Duramed Pharmaceuticals, Inc.
    Inventors: Edward N. Hill, Frederick D. Sancilio, Robert R. Whittle
  • Novel Estrogenic Compounds
    Publication number: 20100234330
    Abstract: Novel estrogenic compounds of Formula I are provided. wherein the bond represented by the wavy line may be a single or double bond such that when the wavy line is a single bond, R1 is selected from the group consisting of hydrogen, sulfate and glucoronate or other esters, and when the wavy line is a double bond, R1 does not exist; R2 is lower alkyl; R3 may be selected from the group consisting of hydrogen, sulfate, or glucuronide or other esters; and R4 through R13 may independently be selected from the group consisting of hydrogen, hydroxy, ketone, lower alkyl, lower alkoxy, halogen, and carbonyl groups and R14 is selected from the group consisting of hydrogen, sulfate and glucoronide and other esters. When R1 is hydroxy, the hydroxy or ester substituent may have either an ? or a ? orientation. Compositions of matter including compounds of the present invention are also provided as are methods of treating mammals in need of treatment using compounds of the present invention.
    Type: Application
    Filed: May 27, 2010
    Publication date: September 16, 2010
    Inventors: Edward N. Hill, Frederick D. Sancilio, Robert R. Whittle
  • Estrogenic compounds, methods of using and methods of administering the same
    Patent number: 7749989
    Abstract: Novel estrogenic compounds of Formula I are provided. wherein the bond represented by the wavy line may be a single or double bond such that when the wavy line is a single bond, R1 is selected from the group consisting of hydrogen, sulfate and glucoronate or other esters, and when the wavy line is a double bond, R1 does not exist; R2 is lower alkyl; R3 may be selected from the group consisting of hydrogen, sulfate, or glucuronide or other esters; and R4 through R13 may independently be selected from the group consisting of hydrogen, hydroxy, ketone, lower alkyl, lower alkoxy, halogen, and carbonyl groups and R14 is selected from the group consisting of hydrogen, sulfate and glucoronide and other esters. When R1 is hydroxy, the hydroxy or ester substituent may have either an ? or a ? orientation. Compositions of matter including compounds of the present invention are also provided as are methods of treating mammals in need of treatment using compounds of the present invention.
    Type: Grant
    Filed: November 24, 2008
    Date of Patent: July 6, 2010
    Assignee: Duramed Pharmaceuticals, Inc.
    Inventors: Edward N. Hill, Frederick D. Sancilio, Robert R. Whittle
  • NOVEL ESTROGENIC COMPOUNDS
    Publication number: 20090105198
    Abstract: Novel estrogenic compounds of Formula I are provided. wherein the bond represented by the wavy line may be a single or double bond such that when the wavy line is a single bond, R1 is selected from the group consisting of hydrogen, sulfate and glucoronate or other esters, and when the wavy line is a double bond, R1 does not exist; R2 is lower alkyl; R3 may be selected from the group consisting of hydrogen, sulfate, or glucuronide or other esters; and R4 through R13 may independently be selected from the group consisting of hydrogen, hydroxy, ketone, lower alkyl, lower alkoxy, halogen, and carbonyl groups and R14 is selected from the group consisting of hydrogen, sulfate and glucoronide and other esters. When R1 is hydroxy, the hydroxy or ester substituent may have either an ? or a ? orientation. Compositions of matter including compounds of the present invention are also provided as are methods of treating mammals in need of treatment using compounds of the present invention.
    Type: Application
    Filed: November 24, 2008
    Publication date: April 23, 2009
    Inventors: Edward N. Hill, Frederick D. Sancilio, Robert R. Whittle
  • Estrogenic compounds and topical pharmaceutical formulations of the same
    Patent number: 7459445
    Abstract: Novel estrogenic compounds of Formula I are provided. wherein the bond represented by the wavy line may be a single or double bond such that when the wavy line is a single bond, R1 is selected from the group consisting of hydrogen, sulfate and glucoronate or other esters, and when the wavy line is a double bond, R1 does not exist; R2 is lower alkyl; R3 may be selected from the group consisting of hydrogen, sulfate, or glucuronide or other esters; and R4 through R13 may independently be selected from the group consisting of hydrogen, hydroxy, ketone, lower alkyl, lower alkoxy, halogen, and carbonyl groups and R14 is selected from the group consisting of hydrogen, sulfate and glucoronide and other esters. When R1 is hydroxy, the hydroxy or ester substituent may have either an ? or a ? orientation. Compositions of matter including compounds of the present invention are also provided as are methods of treating mammals in need of treatment using compounds of the present invention.
    Type: Grant
    Filed: February 6, 2007
    Date of Patent: December 2, 2008
    Assignee: Duramed Pharmaceuticals, Inc.
    Inventors: Edward N. Hill, Frederick D. Sancilio, Robert R. Whittle
  • (3) and (6) substituted estrogenic compounds
    Patent number: 7179799
    Abstract: Novel estrogenic compounds of Formula I are provided. wherein the bond represented by the wavy line may be a single or double bond such that when the wavy line is a single bond, R1 is selected from the group consisting of hydrogen, sulfate and glucoronate or other esters, and when the wavy line is a double bond, R1 does not exist; R2 is lower alkyl; R3 may be selected from the group consisting of hydrogen, sulfate, or glucuronide or other esters; and R4 through R13 may independently be selected from the group consisting of hydrogen, hydroxy, ketone, lower allyl, lower alkoxy, halogen, and carbonyl groups and R14 is selected from the group consisting of hydrogen, sulfate and glucoronide and other esters. When R1 is hydroxy, the hydroxy or ester substituent may have either an ? or a ? orientation. Compositions of matter including compounds of the present invention are also provided as are methods of treating mammals in need of treatment using compounds of the present invention.
    Type: Grant
    Filed: July 23, 2003
    Date of Patent: February 20, 2007
    Assignee: Barr Laboratories, Inc.
    Inventors: Edward N. Hill, Frederick D. Sancilio, Robert R. Whittle
  • C(14) estrogenic compounds
    Patent number: 6992075
    Abstract: The present invention relates to novel estrogenic compounds. The present invention also relates to methods of treating estrogen deprivation in a subject comprising administering novel estrogenic compounds. Additionally, the present invention relates to methods of synthesizing novel estrogenic compounds.
    Type: Grant
    Filed: April 4, 2003
    Date of Patent: January 31, 2006
    Assignee: Barr Laboratories, Inc.
    Inventors: Edward N. Hill, Thomas W. Leonard, Robert R. Whittle
  • Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds
    Patent number: 6855703
    Abstract: A composition of matter is provided having a mixture of active estrogenic compounds. The mixture is present in chemically pure form. The mixture includes salts of conjugated estrone, conjugated equilin, conjugated ?8,9-dehydroestrone, conjugated 17?-estradiol, conjugated 17?-dihydroequilin, conjugated 17?-dihydroequilin, conjugated 17?-estradiol, conjugated equilenin, conjugated 17?-dihydroequilenin, and conjugated 17?-dihydroequilenin. The mixture also contains the same essential estrogenic compounds present in naturally derived equine conjugated estrogens. Drug products including the composition of matter are also provided, as are methods of using these drug products to treat mammals in need of treatment. Methods of analyzing mixtures containing conjugated estrogens are also provided.
    Type: Grant
    Filed: March 10, 2000
    Date of Patent: February 15, 2005
    Assignee: Endeavor Pharmaceuticals
    Inventors: Edward N. Hill, Thomas W. Leonard, Frederick D. Sancilio, Katherin M. Schlipp, Dean G. Shirazi, Robert R. Whittle
  • (3) and (6) substitued estrogenic compounds
    Patent number: 6844334
    Abstract: Novel estrogenic compounds of Formula I are provided. wherein the bond represented by the wavy line may be a single or double bond such that when the wavy line is a single bond, R1 is selected from the group consisting of hydrogen, sulfate and glucoronate or other esters, and when the wavy line is a double bond, R1 does not exist; R2 is lower alkyl; R3 may be selected from the group consisting of hydrogen, sulfate, or glucuronide or other esters; and R4 through R13 may independently be selected from the group consisting of hydrogen, hydroxy, ketone, lower alkyl, lower alkoxy, halogen, and carbonyl groups and R14 is selected from the group consisting of hydrogen, sulfate and glucoronide and other esters. When R1 is hydroxy, the hydroxy or ester substituent may have either an ? or a ? orientation. Compositions of matter including compounds of the present invention are also provided as are methods of treating mammals in need of treatment using compounds of the present invention.
    Type: Grant
    Filed: May 15, 2003
    Date of Patent: January 18, 2005
    Assignee: Endeavor Pharmaceuticals
    Inventors: Edward N. Hill, Frederick D. Sancilio, Robert R. Whittle
  • Novel estrogenic compounds
    Publication number: 20040198670
    Abstract: The present invention relates to novel estrogenic compounds. The present invention also relates to methods of treating estrogen deprivation in a subject comprising administering novel estrogenic compounds. Additionally, the present invention relates to methods of synthesizing novel estrogenic compounds.
    Type: Application
    Filed: April 4, 2003
    Publication date: October 7, 2004
    Inventors: Edward N. Hill, Thomas W. Leonard, Robert R. Whittle
  • FT-Raman spectroscopic measurement
    Patent number: 6780880
    Abstract: Fourier Transform Raman Spectroscopy (FT-Raman) determines the isomer ratio of chemical compositions.
    Type: Grant
    Filed: August 25, 2000
    Date of Patent: August 24, 2004
    Inventors: Robert R. Whittle, Frederick D. Sancilio, Grayson Walker Stowell
  • Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
    Publication number: 20040157887
    Abstract: Compounds represented by formula (Ia) are disclosed by the invention, along with compositions and complexes thereof, optionally in combination with compounds of formula (Ib). Pharmaceutical formulations and methods of making and using such compounds are also disclosed.
    Type: Application
    Filed: February 2, 2004
    Publication date: August 12, 2004
    Inventors: Robert R. Whittle, Frederick D. Sancilio, Grayson Walker Stowell, Douglas John Jenkins, Linda B. Whittall
  • Novel estrogenic compounds
    Publication number: 20040147496
    Abstract: Novel estrogenic compounds of Formula I are provided.
    Type: Application
    Filed: July 23, 2003
    Publication date: July 29, 2004
    Inventors: Edward N. Hill, Frederick D. Sancilio, Robert R. Whittle
  • Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
    Patent number: 6706737
    Abstract: Compounds represented by formula (Ia) are disclosed by the invention, along with compositions and complexes thereof, optionally in combination with compounds of formula (Ib). Pharmaceutical formulations and methods of making and using such compounds are also disclosed.
    Type: Grant
    Filed: May 8, 2003
    Date of Patent: March 16, 2004
    Inventors: Robert R. Whittle, Frederick D. Sancilio, Grayson Walker Stowell, Douglas John Jenkins
  • Process for purifying 6-methoxy omeprazole
    Patent number: 6673936
    Abstract: The present invention provides processes for purifying 6-methoxy omeprazole, products using such processes, pharmaceutical formulations using such products, and methods of using such products for gastric acid inhibition.
    Type: Grant
    Filed: April 20, 2001
    Date of Patent: January 6, 2004
    Inventors: Linda B. Whittall, Grayson Walker Stowell, Robert R. Whittle
  • Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
    Patent number: 6667321
    Abstract: Compounds represented by formula (Ia) are disclosed by the invention, along with compositions and complexes thereof, optionally in combination with compounds of formula (Ib). Pharmaceutical formulations and methods of making and using such compounds are also disclosed.
    Type: Grant
    Filed: July 3, 2002
    Date of Patent: December 23, 2003
    Inventors: Robert R. Whittle, Frederick D. Sancilio, Grayson Walker Stowell, Douglas John Jenkins, Linda B. Whittall
  • Dry-blend pharmaceutical formulations
    Patent number: 6667323
    Abstract: Compounds represented by formula (Ia) are disclosed by the invention, along with compositions and complexes thereof, optionally in combination with compounds of formula (Ib). Pharmaceutical formulations and methods of making and using such compounds are also disclosed.
    Type: Grant
    Filed: May 7, 2003
    Date of Patent: December 23, 2003
    Inventors: Robert R. Whittle, Frederick D. Sancilio, Grayson Walker Stowell, Douglas John Jenkins, Linda D. Whittall
  • Dry blend pharmaceutical formulations
    Patent number: 6667324
    Abstract: Compounds represented by formula (Ia) are disclosed by the invention, along with compositions and complexes thereof, optionally in combination with compounds of formula (Ib). Pharmaceutical formulations and methods of making and using such compounds are also disclosed.
    Type: Grant
    Filed: May 16, 2003
    Date of Patent: December 23, 2003
    Inventors: Robert R. Whittle, Frederick D. Sancilio, Grayson Walker Stowell, Douglas John Jenkins, Linda B. Whittall